Perrigo’s Rx-To-OTC Contraceptive Pill Switch Unanimously Rejected By German Committee
All nine present voting members of Germany's Expert Committee for Prescription rejected Perrigo's application to switch its progestogen-only contraceptive pill (desogestrel 75μg) from Rx to OTC status.
You may also be interested in...
Perrigo says 2024 results will be slowed by investment in companywide efficiency project including staff reductions. After Opill’s expected launch by late March, sales will be dilutive to earnings for the first year partly due to investments in the brand, primarily at retailers and online in Q2.
Pressure from members of Congress and public and reproductive health advocacy groups will continue for making Opill’s price affordable to consumers from all income levels, but competition won’t affect the price for three years.
“We do want to be a mega brand offering solutions across the women's sexual health journey. From the moment she enters into that category all the way through to post menopause, including fertility, we will develop out a mega brand,” says CEO Patrick Lockwood-Taylor.